Estradiol	B:C0014912
prodrugs	O
(	O
Estradiol	O
prodrugs	I:C0033262
)	O
for	O
efficient	O
oral	O
estrogen	O
treatment	O
and	O
abolished	O
effects	O
on	O
estrogen	O
modulated	O
liver	O
functions	I:C0232741
.	O

Estradiol	O
prodrugs	B:C0033262
(	O
Estradiol	O
prodrugs	I:C0033262
)	O
for	O
efficient	O
oral	O
estrogen	O
treatment	O
and	O
abolished	O
effects	O
on	O
estrogen	O
modulated	O
liver	O
functions	I:C0232741
.	O

Estradiol	O
prodrugs	O
(	O
Estradiol	B:C0033262
prodrugs	I:C0033262
)	O
for	O
efficient	O
oral	O
estrogen	O
treatment	O
and	O
abolished	O
effects	O
on	O
estrogen	O
modulated	O
liver	O
functions	I:C0232741
.	O

Estradiol	O
prodrugs	O
(	O
Estradiol	O
prodrugs	I:C0033262
)	O
for	O
efficient	O
oral	B:C0001563
estrogen	O
treatment	O
and	O
abolished	O
effects	O
on	O
estrogen	O
modulated	O
liver	O
functions	I:C0232741
.	O

Estradiol	O
prodrugs	O
(	O
Estradiol	O
prodrugs	I:C0033262
)	O
for	O
efficient	O
oral	O
estrogen	O
treatment	O
and	O
abolished	O
effects	O
on	O
estrogen	B:C0014939
modulated	O
liver	O
functions	I:C0232741
.	O

Estradiol	O
prodrugs	O
(	O
Estradiol	O
prodrugs	I:C0033262
)	O
for	O
efficient	O
oral	O
estrogen	O
treatment	O
and	O
abolished	O
effects	O
on	O
estrogen	O
modulated	O
liver	B:C0232741
functions	I:C0232741
.	O

Oral	B:C0001563
compared	O
to	O
parenteral	O
estrogen	O
administration	O
is	O
characterized	O
by	O
reduced	O
systemic	O
but	O
prominent	O
hepatic	O
estrogenic	O
effects	I:C0877035
on	O
lipids	O
,	O
hemostatic	O
factors	I:C0019116
,	O
GH	O
-/	O
IGF	O
I	I:C0021665
axis	O
,	O
angiotensinogen	O
.	O

Oral	O
compared	O
to	O
parenteral	O
estrogen	O
administration	O
is	O
characterized	O
by	O
reduced	O
systemic	O
but	O
prominent	O
hepatic	B:C0205054
estrogenic	O
effects	I:C0877035
on	O
lipids	O
,	O
hemostatic	O
factors	I:C0019116
,	O
GH	O
-/	O
IGF	O
I	I:C0021665
axis	O
,	O
angiotensinogen	O
.	O

Oral	O
compared	O
to	O
parenteral	O
estrogen	O
administration	O
is	O
characterized	O
by	O
reduced	O
systemic	O
but	O
prominent	O
hepatic	O
estrogenic	B:C0877035
effects	I:C0877035
on	O
lipids	O
,	O
hemostatic	O
factors	I:C0019116
,	O
GH	O
-/	O
IGF	O
I	I:C0021665
axis	O
,	O
angiotensinogen	O
.	O

Oral	O
compared	O
to	O
parenteral	O
estrogen	O
administration	O
is	O
characterized	O
by	O
reduced	O
systemic	O
but	O
prominent	O
hepatic	O
estrogenic	O
effects	I:C0877035
on	O
lipids	B:C0023779
,	O
hemostatic	O
factors	I:C0019116
,	O
GH	O
-/	O
IGF	O
I	I:C0021665
axis	O
,	O
angiotensinogen	O
.	O

Oral	O
compared	O
to	O
parenteral	O
estrogen	O
administration	O
is	O
characterized	O
by	O
reduced	O
systemic	O
but	O
prominent	O
hepatic	O
estrogenic	O
effects	I:C0877035
on	O
lipids	O
,	O
hemostatic	B:C0019116
factors	I:C0019116
,	O
GH	O
-/	O
IGF	O
I	I:C0021665
axis	O
,	O
angiotensinogen	O
.	O

Oral	O
compared	O
to	O
parenteral	O
estrogen	O
administration	O
is	O
characterized	O
by	O
reduced	O
systemic	O
but	O
prominent	O
hepatic	O
estrogenic	O
effects	I:C0877035
on	O
lipids	O
,	O
hemostatic	O
factors	I:C0019116
,	O
GH	B:C0037663
-/	O
IGF	O
I	I:C0021665
axis	O
,	O
angiotensinogen	O
.	O

Oral	O
compared	O
to	O
parenteral	O
estrogen	O
administration	O
is	O
characterized	O
by	O
reduced	O
systemic	O
but	O
prominent	O
hepatic	O
estrogenic	O
effects	I:C0877035
on	O
lipids	O
,	O
hemostatic	O
factors	I:C0019116
,	O
GH	O
-/	O
IGF	B:C0021665
I	I:C0021665
axis	O
,	O
angiotensinogen	O
.	O

Oral	O
compared	O
to	O
parenteral	O
estrogen	O
administration	O
is	O
characterized	O
by	O
reduced	O
systemic	O
but	O
prominent	O
hepatic	O
estrogenic	O
effects	I:C0877035
on	O
lipids	O
,	O
hemostatic	O
factors	I:C0019116
,	O
GH	O
-/	O
IGF	O
I	I:C0021665
axis	O
,	O
angiotensinogen	B:C0003017
.	O

In	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	O
effects	O
of	O
oral	B:C0001563
treatment	I:C0001563
,	O
estradiol	O
(	O
E2	O
)	O
prodrugs	O
(	O
Estradiol	O
prodrugs	I:C0033262
)	O
were	O
designed	O
which	O
bypass	O
the	O
liver	O
tissue	I:C0736268
as	O
inactive	O
molecules	O
.	O

In	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	O
effects	O
of	O
oral	O
treatment	I:C0001563
,	O
estradiol	B:C0014912
(	O
E2	O
)	O
prodrugs	O
(	O
Estradiol	O
prodrugs	I:C0033262
)	O
were	O
designed	O
which	O
bypass	O
the	O
liver	O
tissue	I:C0736268
as	O
inactive	O
molecules	O
.	O

In	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	O
effects	O
of	O
oral	O
treatment	I:C0001563
,	O
estradiol	O
(	O
E2	B:C0014912
)	O
prodrugs	O
(	O
Estradiol	O
prodrugs	I:C0033262
)	O
were	O
designed	O
which	O
bypass	O
the	O
liver	O
tissue	I:C0736268
as	O
inactive	O
molecules	O
.	O

In	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	O
effects	O
of	O
oral	O
treatment	I:C0001563
,	O
estradiol	O
(	O
E2	O
)	O
prodrugs	B:C0033262
(	O
Estradiol	O
prodrugs	I:C0033262
)	O
were	O
designed	O
which	O
bypass	O
the	O
liver	O
tissue	I:C0736268
as	O
inactive	O
molecules	O
.	O

In	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	O
effects	O
of	O
oral	O
treatment	I:C0001563
,	O
estradiol	O
(	O
E2	O
)	O
prodrugs	O
(	O
Estradiol	B:C0033262
prodrugs	I:C0033262
)	O
were	O
designed	O
which	O
bypass	O
the	O
liver	O
tissue	I:C0736268
as	O
inactive	O
molecules	O
.	O

In	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	O
effects	O
of	O
oral	O
treatment	I:C0001563
,	O
estradiol	O
(	O
E2	O
)	O
prodrugs	O
(	O
Estradiol	O
prodrugs	I:C0033262
)	O
were	O
designed	O
which	O
bypass	O
the	O
liver	B:C0736268
tissue	I:C0736268
as	O
inactive	O
molecules	O
.	O

Carbone17	O
-	O
OH	O
sulfonamide	O
[	O
-	O
O2	O
-	O
NH2	O
]	O
substituted	O
esters	O
of	O
E2	B:C0014912
(	O
EC508	O
,	O
others	O
)	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic	O
anhydrase	I:C0007034
II	I:C0007034
(	O
carbonic	O
anhydrase	I:C0007034
II	I:C0007034
)	O
binding	O
.	O

Carbone17	O
-	O
OH	O
sulfonamide	O
[	O
-	O
O2	O
-	O
NH2	O
]	O
substituted	O
esters	O
of	O
E2	O
(	O
EC508	B:C0014912
,	O
others	O
)	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic	O
anhydrase	I:C0007034
II	I:C0007034
(	O
carbonic	O
anhydrase	I:C0007034
II	I:C0007034
)	O
binding	O
.	O

Carbone17	O
-	O
OH	O
sulfonamide	O
[	O
-	O
O2	O
-	O
NH2	O
]	O
substituted	O
esters	O
of	O
E2	O
(	O
EC508	O
,	O
others	O
)	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic	B:C0007034
anhydrase	I:C0007034
II	I:C0007034
(	O
carbonic	O
anhydrase	I:C0007034
II	I:C0007034
)	O
binding	O
.	O

Carbone17	O
-	O
OH	O
sulfonamide	O
[	O
-	O
O2	O
-	O
NH2	O
]	O
substituted	O
esters	O
of	O
E2	O
(	O
EC508	O
,	O
others	O
)	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic	O
anhydrase	I:C0007034
II	I:C0007034
(	O
carbonic	B:C0007034
anhydrase	I:C0007034
II	I:C0007034
)	O
binding	O
.	O

Carbone17	O
-	O
OH	O
sulfonamide	O
[	O
-	O
O2	O
-	O
NH2	O
]	O
substituted	O
esters	O
of	O
E2	O
(	O
EC508	O
,	O
others	O
)	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic	O
anhydrase	I:C0007034
II	I:C0007034
(	O
carbonic	O
anhydrase	I:C0007034
II	I:C0007034
)	O
binding	B:C1149286
.	O

CA	B:C0007034
II	I:C0007034
in	O
erythrocytes	O
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
Estradiol	O
prodrugs	I:C0033262
from	O
portal	O
vein	I:C2324289
blood	I:C2324289
during	O
liver	O
passage	O
.	O

CA	O
II	I:C0007034
in	O
erythrocytes	B:C0014792
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
Estradiol	O
prodrugs	I:C0033262
from	O
portal	O
vein	I:C2324289
blood	I:C2324289
during	O
liver	O
passage	O
.	O

CA	O
II	I:C0007034
in	O
erythrocytes	O
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
Estradiol	B:C0033262
prodrugs	I:C0033262
from	O
portal	O
vein	I:C2324289
blood	I:C2324289
during	O
liver	O
passage	O
.	O

CA	O
II	I:C0007034
in	O
erythrocytes	O
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
Estradiol	O
prodrugs	I:C0033262
from	O
portal	B:C2324289
vein	I:C2324289
blood	I:C2324289
during	O
liver	O
passage	O
.	O

CA	O
II	I:C0007034
in	O
erythrocytes	O
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
Estradiol	O
prodrugs	I:C0033262
from	O
portal	O
vein	I:C2324289
blood	I:C2324289
during	O
liver	B:C0023884
passage	O
.	O

CA	O
II	I:C0007034
in	O
erythrocytes	O
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
Estradiol	O
prodrugs	I:C0033262
from	O
portal	O
vein	I:C2324289
blood	I:C2324289
during	O
liver	O
passage	B:C0439799
.	O

Ovariectomized	O
(	O
OVX	O
,	O
day	O
minus	O
14	O
)	O
rats	B:C0034721
were	O
orally	O
treated	I:C0001563
once	O
daily	O
from	O
day	O
1	O
-	O
3	O
.	O

Ovariectomized	O
(	O
OVX	O
,	O
day	O
minus	O
14	O
)	O
rats	O
were	O
orally	B:C0001563
treated	I:C0001563
once	O
daily	O
from	O
day	O
1	O
-	O
3	O
.	O

Uteri	B:C0042149
were	O
dissected	O
and	O
weighed	O
.	O

Uteri	O
were	O
dissected	O
and	O
weighed	B:C3827964
.	O

Cholesterol	B:C0201950
fractions	I:C0201950
and	O
angiotensinogen	O
were	O
determined	O
in	O
plasma	O
.	O

Cholesterol	O
fractions	I:C0201950
and	O
angiotensinogen	B:C0523500
were	O
determined	O
in	O
plasma	O
.	O

Cholesterol	O
fractions	I:C0201950
and	O
angiotensinogen	O
were	O
determined	O
in	O
plasma	B:C0032105
.	O

Oral	O
E2	O
and	O
ethinyl	B:C0015011
estradiol	I:C0015011
(	O
ethinyl	O
estradiol	I:C0015011
)	O
generated	O
dose	O
related	O
uterine	O
growth	O
and	O
important	O
hepatic	O
estrogenic	O
effects	I:C0877035
.	O

Oral	O
E2	O
and	O
ethinyl	O
estradiol	I:C0015011
(	O
ethinyl	B:C0015011
estradiol	I:C0015011
)	O
generated	O
dose	O
related	O
uterine	O
growth	O
and	O
important	O
hepatic	O
estrogenic	O
effects	I:C0877035
.	O

Oral	O
E2	O
and	O
ethinyl	O
estradiol	I:C0015011
(	O
ethinyl	O
estradiol	I:C0015011
)	O
generated	O
dose	O
related	O
uterine	B:C0042149
growth	O
and	O
important	O
hepatic	O
estrogenic	O
effects	I:C0877035
.	O

Oral	O
E2	O
and	O
ethinyl	O
estradiol	I:C0015011
(	O
ethinyl	O
estradiol	I:C0015011
)	O
generated	O
dose	O
related	O
uterine	O
growth	B:C0018270
and	O
important	O
hepatic	O
estrogenic	O
effects	I:C0877035
.	O

Oral	O
E2	O
and	O
ethinyl	O
estradiol	I:C0015011
(	O
ethinyl	O
estradiol	I:C0015011
)	O
generated	O
dose	O
related	O
uterine	O
growth	O
and	O
important	O
hepatic	B:C0205054
estrogenic	O
effects	I:C0877035
.	O

Oral	O
E2	O
and	O
ethinyl	O
estradiol	I:C0015011
(	O
ethinyl	O
estradiol	I:C0015011
)	O
generated	O
dose	O
related	O
uterine	O
growth	O
and	O
important	O
hepatic	O
estrogenic	B:C0877035
effects	I:C0877035
.	O

Estradiol	B:C0033262
prodrugs	I:C0033262
induced	O
uterine	O
growth	I:C1326619
at	O
about	O
hundred	O
-	O
fold	O
lower	O
doses	O
.	O

Estradiol	O
prodrugs	I:C0033262
induced	O
uterine	B:C1326619
growth	I:C1326619
at	O
about	O
hundred	O
-	O
fold	O
lower	O
doses	O
.	O

This	O
was	O
possible	O
with	O
almost	O
absent	O
effects	O
on	O
plasma	B:C0032105
cholesterol	O
or	O
angiotensinogen	O
.	O

This	O
was	O
possible	O
with	O
almost	O
absent	O
effects	O
on	O
plasma	O
cholesterol	B:C0008377
or	O
angiotensinogen	O
.	O

This	O
was	O
possible	O
with	O
almost	O
absent	O
effects	O
on	O
plasma	O
cholesterol	O
or	O
angiotensinogen	B:C0003017
.	O

Preliminary	O
pharmacokinetic	B:C0201734
studies	I:C0201734
with	O
EC508	O
used	O
intravenous	O
and	O
oral	O
administration	I:C0001563
in	O
male	O
rats	O
.	O

Preliminary	O
pharmacokinetic	O
studies	I:C0201734
with	O
EC508	B:C0014912
used	O
intravenous	O
and	O
oral	O
administration	I:C0001563
in	O
male	O
rats	O
.	O

Preliminary	O
pharmacokinetic	O
studies	I:C0201734
with	O
EC508	O
used	O
intravenous	B:C0013125
and	O
oral	O
administration	I:C0001563
in	O
male	O
rats	O
.	O

Preliminary	O
pharmacokinetic	O
studies	I:C0201734
with	O
EC508	O
used	O
intravenous	O
and	O
oral	B:C0001563
administration	I:C0001563
in	O
male	O
rats	O
.	O

Preliminary	O
pharmacokinetic	O
studies	I:C0201734
with	O
EC508	O
used	O
intravenous	O
and	O
oral	O
administration	I:C0001563
in	O
male	O
rats	B:C0034721
.	O

Resulting	O
blood	O
levels	O
revealed	O
complete	O
oral	B:C0001563
bioavailability	O
.	O

Further	O
high	O
blood	B:C0005767
-	O
but	O
low	O
plasma	O
concentrations	O
indicated	O
erythrocyte	O
binding	O
of	O
EC508	O
in	O
vivo	I:C1515655
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	O
passage	O
.	O

Further	O
high	O
blood	O
-	O
but	O
low	O
plasma	B:C0032105
concentrations	O
indicated	O
erythrocyte	O
binding	O
of	O
EC508	O
in	O
vivo	I:C1515655
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	O
passage	O
.	O

Further	O
high	O
blood	O
-	O
but	O
low	O
plasma	O
concentrations	O
indicated	O
erythrocyte	B:C0014792
binding	O
of	O
EC508	O
in	O
vivo	I:C1515655
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	O
passage	O
.	O

Further	O
high	O
blood	O
-	O
but	O
low	O
plasma	O
concentrations	O
indicated	O
erythrocyte	O
binding	O
of	O
EC508	B:C0014912
in	O
vivo	I:C1515655
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	O
passage	O
.	O

Further	O
high	O
blood	O
-	O
but	O
low	O
plasma	O
concentrations	O
indicated	O
erythrocyte	O
binding	O
of	O
EC508	O
in	B:C1515655
vivo	I:C1515655
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	O
passage	O
.	O

Further	O
high	O
blood	O
-	O
but	O
low	O
plasma	O
concentrations	O
indicated	O
erythrocyte	O
binding	O
of	O
EC508	O
in	O
vivo	I:C1515655
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	B:C0023884
passage	O
.	O

Further	O
high	O
blood	O
-	O
but	O
low	O
plasma	O
concentrations	O
indicated	O
erythrocyte	O
binding	O
of	O
EC508	O
in	O
vivo	I:C1515655
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	O
passage	B:C0439799
.	O

Very	O
high	O
systemic	O
estrogenicity	B:C0014939
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	O
estrogenic	O
effects	I:C0877035
is	O
evidence	O
for	O
a	O
systemic	O
release	O
of	O
E2	O
from	O
sulfonamide	O
EP	I:C0033262
.	O

Very	O
high	O
systemic	O
estrogenicity	O
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	B:C0205054
estrogenic	O
effects	I:C0877035
is	O
evidence	O
for	O
a	O
systemic	O
release	O
of	O
E2	O
from	O
sulfonamide	O
EP	I:C0033262
.	O

Very	O
high	O
systemic	O
estrogenicity	O
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	O
estrogenic	B:C0877035
effects	I:C0877035
is	O
evidence	O
for	O
a	O
systemic	O
release	O
of	O
E2	O
from	O
sulfonamide	O
EP	I:C0033262
.	O

Very	O
high	O
systemic	O
estrogenicity	O
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	O
estrogenic	O
effects	I:C0877035
is	O
evidence	O
for	O
a	O
systemic	O
release	O
of	O
E2	B:C0014912
from	O
sulfonamide	O
EP	I:C0033262
.	O

Very	O
high	O
systemic	O
estrogenicity	O
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	O
estrogenic	O
effects	I:C0877035
is	O
evidence	O
for	O
a	O
systemic	O
release	O
of	O
E2	O
from	O
sulfonamide	B:C0033262
EP	I:C0033262
.	O

In	O
conclusion	O
,	O
tested	O
oral	B:C0001563
Estradiol	O
prodrugs	I:C0033262
bypass	O
the	O
liver	O
in	O
erythrocytes	O
furnishing	O
systemic	O
estradiol	O
at	O
hydrolysis	O
.	O

In	O
conclusion	O
,	O
tested	O
oral	O
Estradiol	B:C0033262
prodrugs	I:C0033262
bypass	O
the	O
liver	O
in	O
erythrocytes	O
furnishing	O
systemic	O
estradiol	O
at	O
hydrolysis	O
.	O

In	O
conclusion	O
,	O
tested	O
oral	O
Estradiol	O
prodrugs	I:C0033262
bypass	O
the	O
liver	B:C0023884
in	O
erythrocytes	O
furnishing	O
systemic	O
estradiol	O
at	O
hydrolysis	O
.	O

In	O
conclusion	O
,	O
tested	O
oral	O
Estradiol	O
prodrugs	I:C0033262
bypass	O
the	O
liver	O
in	O
erythrocytes	B:C0014792
furnishing	O
systemic	O
estradiol	O
at	O
hydrolysis	O
.	O

In	O
conclusion	O
,	O
tested	O
oral	O
Estradiol	O
prodrugs	I:C0033262
bypass	O
the	O
liver	O
in	O
erythrocytes	O
furnishing	O
systemic	O
estradiol	B:C0014912
at	O
hydrolysis	O
.	O

This	O
mechanism	O
avoids	O
the	O
hepatic	B:C0205054
estrogenic	O
impact	O
of	O
conventional	O
oral	O
estrogen	O
therapy	I:C0279494
.	O

This	O
mechanism	O
avoids	O
the	O
hepatic	O
estrogenic	O
impact	O
of	O
conventional	O
oral	B:C0001563
estrogen	O
therapy	I:C0279494
.	O

This	O
mechanism	O
avoids	O
the	O
hepatic	O
estrogenic	O
impact	O
of	O
conventional	O
oral	O
estrogen	B:C0279494
therapy	I:C0279494
.	O

